Default company panoramic image


Aura is a drug development company using synthetic biology to develop novel cancer drugs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Mid-Cambridge, Cambridge, MA, USA
  • Currency USD
  • Founded January 2009
  • Employees 8
  • Website

Company Summary

Aura Biosciences is a drug development oncology company . The technology is based on synthetic viruses that can target drugs to tumors with a unique mechanism of action. We have a solid IP portfolio, with an exclusive license from the National Cancer Institute. Our lead candidate is in late pre-clinical development for a rare cancer indication, ocular melanoma. We have key support from seasoned pharma investors including Henri Termeer.


  • Default avatar
    Elisabet de los Pinos

    Eli is the founding CEO . Prior to Aura, she was part of Eli Lilly's leadership team responsible for Alimta’s market launch in Europe. Eli holds a Ph.D. in Molecular Biology from the University of Barcelona, and is a fellow of the Entrepreneurship Development Program at MIT Sloan School of Management . She is a Tech Pioneer at the World Economic Forum and a member of the Board of Overseers at the Museum of Science in Boston.

  • Default avatar
    Peter Elliott
    Interim Head Clinical Development

    Peter holds a BSc in Pharmacology from London University and a PhD from Cambridge University . Peter was VP of Pharmacology and Development at Millenium and was a co-developer of Velcade©. Peter was then SVP of Research & Development at Sirtris where he led their programs dedicated to the discovery and development drugs for metabolic disorders, oncology, inflammation and neurodegenerative disorders.

  • Default avatar
    John MacDougall
    Director of Research

    John received a B.Sc. in Toxicology from the University of Guelph (Canada) and a Ph.D. in Cancer Biology at the University of Toronto (Canada). He later joined Infinity Pharmaceuticals leading its pre-clinical pharmacology group. At Infinity, John’s team was responsible for executing discovery and IND enabling studies to support drug candidate selection and mechanistic understanding of Infinity’s portfolio of agents.

  • Default avatar
    Andrew Russell
    Director of Manufacturing

    Andrew received a B.Sc in Biochemistry from the University of Liverpool (UK) and an M.Sc and Ph.D in Biochemical Engineering from the University of London (UK). Andrew spent 28 years at Eli Lilly in Bioprocess Development, Commercialization and Manufacturing. He is technical expert in conventional fermentation technology bioprocess scale-up, validation and operation. Products where he has played significant roles include Forteo® , Humulin®, Hu


  • Default avatar
    Rubin & Rudman LLP
    Default avatar

Previous Investors

  • Default avatar
    Business Angels